title: Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
authors.forename: B
authors.initials: B
authors.lastname: Poncet
authors.forename: T
authors.initials: T
authors.lastname: Bachelot
authors.forename: C
authors.initials: C
authors.lastname: Colin
authors.forename: H
authors.initials: H
authors.lastname: Orfeuvre
authors.forename: C
authors.initials: C
authors.lastname: Ganne
authors.forename: P Y
authors.initials: PY
authors.lastname: Péaud
authors.forename: J P
authors.initials: JP
authors.lastname: Jacquin
authors.forename: B
authors.initials: B
authors.lastname: Salles
authors.forename: J D
authors.initials: JD
authors.lastname: Tigaud
authors.forename: I
authors.initials: I
authors.lastname: Méchin-Crétinon
authors.forename: F
authors.initials: F
authors.lastname: Maréchal
authors.forename: V
authors.initials: V
authors.lastname: Trillet-Lenoir
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000556:secondary; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab